Johnson & Johnson (NYSE:JNJ) said on Friday it has agreed to acquire Atraverse Medical, Inc., a privately held medical device company focused on technologies for left-heart access and radiofrequency procedures.
Strengthening Cardiac Ablation Portfolio
Atraverse Medical produces the HOTWIRE Transseptal Access System, an FDA-cleared radiofrequency guidewire and generator platform used to access the left atrium during atrial fibrillation procedures.
The system has been deployed in nearly 3,000 clinical cases and includes features such as impedance-sensing automatic energy shutoff, compatibility with a range of sheaths, and enhanced tip visibility under intracardiac echocardiography.
Strategic Rationale
The acquisition is expected to enhance Johnson & Johnson’s cardiac ablation offering, giving electrophysiologists additional tools to treat patients with atrial fibrillation and other heart rhythm disorders.
Deal Timeline
The transaction is anticipated to close in the second quarter of 2026, subject to customary conditions. Financial details of the deal were not disclosed.